Summary of Vor's Presentation at the 44th Annual J.P. Morgan Healthcare Conference Company Overview - **Company**: Vor - **CEO**: Jean-Paul Kress - **Focus**: Transitioning from a cell therapy company to an autoimmune disease powerhouse, referred to as Vor 2.0 [2][16] Key Product: Telitacicept - **Asset**: Telitacicept, an innovative BAFF APRIL inhibitor, aimed at treating autoimmune B-cell mediated diseases [2][3] - **Source**: In-licensed from RemeGen, a company based in China [2][3] - **Clinical Validation**: Over 10,000 patients treated in China, with clinical validation across more than eight autoimmune diseases [4][6] Pipeline and Indications - **Selected Indications**: - Myasthenia Gravis (MG) - Sjögren's Disease [4][11] - **Current Trials**: - Global Phase 3 trial for MG is underway, with plans to start the Sjögren's trial soon [4][10] - **Market Potential**: - MG market in the U.S. projected to reach approximately $10 billion by the end of the decade [7][8] - Sjögren's disease affects around 300,000 patients in the U.S., with 100,000 currently eligible for biologics [11][12] Clinical Efficacy - **Myasthenia Gravis**: - Achieved a significant improvement of -4.8 on the MG-ADL score at week 24, with sustained improvement of 7.5 by week 48 [9][10] - **Sjögren's Disease**: - Demonstrated compelling efficacy in clinical trials, with a focus on disease modification and long-term treatment potential [12][14] Competitive Advantage - **Best-in-Class Profile**: Telitacicept is positioned as the most advanced BAFF APRIL inhibitor globally, with a favorable safety profile and no burdensome vaccination requirements [6][10] - **Learning from Competitors**: Insights gained from Novartis's trials in Sjögren's will enhance Vor's study design and execution [25][31] Financial Position - **Cash Reserves**: Vor has $450 million on its balance sheet, providing a runway until mid-2028 to support ongoing trials and commercial launches [4][33] - **Investment Strategy**: Focus on maximizing current studies while considering future indications for telitacicept [16][29] Team and Expertise - **Leadership Team**: Includes experienced professionals from leading biotech companies, enhancing Vor's capability to execute its strategy [18][19] - **Regulatory Engagement**: Ongoing discussions with regulators to ensure compliance and optimize trial protocols [24][26] Conclusion - Vor is well-positioned to transform the treatment landscape for autoimmune diseases with telitacicept, targeting significant unmet medical needs in MG and Sjögren's disease, backed by a strong financial position and an experienced team [16][17]